Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So

Core Insights - Cogent Biosciences Inc. (NASDAQ:COGT) has seen a significant increase in its stock value, with a notable upward revision of its price target from $21 to $50 by H.C. Wainwright, reaffirming a Buy rating [1][2] - The positive outlook is primarily driven by the results of the Phase 3 PEAK trial, which indicates that the combination of bezuclastinib and sunitinib could become the second-line standard of care for gastrointestinal stromal tumors (GIST) [2][3] - Following the announcement of the trial results, Cogent's shares surged by 119% on the day of the announcement [3] Company Developments - Cogent Biosciences announced the positive results of the Phase 3 PEAK trial on November 10, 2025, and plans to submit a new drug application (NDA) to the U.S. FDA for bezuclastinib in GIST in the first half of 2026 [3][4] - The trial results showed a greater than seven-month improvement in median progression-free survival (mPFS), effectively reducing the rate of progression or death by half for patients with imatinib-resistant or intolerant GIST [4] Industry Context - The results of the PEAK study are seen as a significant advancement for GIST patients, particularly those who have been waiting for nearly 20 years for a new second-line treatment option [4] - The company focuses on developing precision therapies for genetically defined diseases, with a primary emphasis on mastocytosis and gastrointestinal stromal tumors (GIST) [4]